Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight

This is less a macro healthcare signal than a validation of a narrow, underpenetrated orphan market. The important mechanism is not prevalence alone but conversion of undiagnosed respiratory patients into treated patients, which tends to be slow, specialist-led, and sticky once therapy starts. That means broad healthcare ETFs should barely move, while the few companies with direct NTM exposure can earn a scarcity premium if prescription growth compounds.

The likely beneficiary is INSM, because in a small disease pool the value driver is share capture and persistence, not category expansion. Secondary winners are diagnostics and specialty pharmacy channels that sit upstream of treatment initiation; the hidden loser is the old low-efficacy chronic management model, but that displacement is gradual. The market may be overestimating how quickly a higher CAGR becomes earnings, since payer friction and prior auth can cap real-world uptake once prevalence becomes more visible.

Catalyst path matters: over the next 1-3 months, watch commercial data and any updated treatment funnel metrics; over 6-18 months, the key question is whether improved diagnosis actually raises treated patient counts or just surfaces more untreated disease. Contrarian view: consensus may be too optimistic on TAM because NTM is clinically messy, often misclassified, and not every diagnosed patient is a profitable patient. Theses fail if new starts plateau, discontinuation rates rise, or reimbursement tightens despite a growing diagnosis pool.